Cough syrups may soon carry warning saying they shouldn't be given to kids under 4

NEW DELHI: Parents who still keep a bottle of combination cold syrup for toddlers now have a clearer legal line on the pack. The Union health ministry has restricted manufacture, sale and distribution of all fixed dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride unless the label, package insert and promotional literature carry an explicit warning that the medicine shall not be used in children below four years of age.

The restriction was notified as S.O. 4595(E) on 18 August 2026 under Section 26A of the Drugs and Cosmetics Act, 1940, and was summarised by the Press Information Bureau on 22 August. It extends an earlier April 2025 gazette notification, S.O. 1717(E), which had already attached the same under-four warning to certain formulations of that combination. The latest order covers all formulations of the two-ingredient FDC marketed in India.

What the Gazette and PIB say

The government said the step followed recommendations of an Expert Committee and the Drugs Technical Advisory Board. The ministry noted that use of such combinations may pose risks to children below four, and that safer alternatives are available. Manufacturers must display the warning on the label and package insert or promotional literature. The notification takes effect from the date of publication in the Official Gazette.

That under-four message for this FDC is not brand new. In December 2023, the Central Drugs Standard Control Organisation wrote to state drug controllers after a Subject Expert Committee (Pulmonary) discussion, directing that the FDC of chlorpheniramine maleate 2 mg plus phenylephrine hydrochloride 5 mg per ml should not be used in children below four, and that firms must print the warning on label and package insert. The August 2026 gazette widens and hardens that approach across all formulations containing the two drugs.

Why schools and parents keep hearing about cough syrups

Cough and cold syrups sit at the noisy intersection of pharmacy counters, boarding-school infirmary cupboards and anxious midnight parent groups. After child deaths in Madhya Pradesh and Rajasthan were linked in public discussion to cough syrup use in late 2025, the Directorate General of Health Services issued an advisory on 3 October 2025 to all State and Union Territory health departments and healthcare facilities on the rational use of paediatric cough syrups. The Press Information Bureau later recorded that advisory in a Lok Sabha reply summarising the Centre's follow-up actions.

The same parliamentary reply noted that more than 1,100 cough syrup manufacturers had been put through intense audit with state authorities, that market surveillance sampling of syrup formulations had been stepped up, and that the Drugs Controller (India) had issued further directions in October 2025 on testing compliance and vigilance against spurious or substandard drugs. Separately, the Indian Pharmacopoeia Commission amended IP 2022 to mandate testing for diethylene glycol and ethylene glycol in oral liquids at the finished-product stage before market release.

For village retail, another rule change closed a quiet loophole. Gazette notification G.S.R. 927(E) dated 29 December 2025 omitted the word "Syrup" from a Schedule K entry that had allowed cough syrup sales in villages with a population under 1,000 without certain retail licensing requirements. A June 2026 PIB note explained that cough syrups in those settings must now move only through duly licensed pharmacies.

What this means on a school desk

This Education desk keeps meeting the same parent question after every viral post: can I give my preschooler that pink syrup? The official answer for chlorpheniramine-phenylephrine combination products is now blunt. Do not use them below four. The October 2025 DGHS advisory pushed the wider paediatric caution further up the chain, asking facilities to prescribe and dispense cough medicines in children with care and to prefer non-drug first-line measures such as hydration and rest where clinical judgment allows.

WHO and paediatric bodies have for years warned that cough and cold medicines can sedate young children, depress breathing and offer little proven benefit for ordinary viral coughs in the youngest age groups. India's own labelling and advisory trail now tracks that concern in black letter for a widely sold FDC, and in operational guidance for health departments after last year's syrup scares.

Further talk of a red, bottle-wide warning and school-age pictorials on cough syrup packs more generally has circulated in public discussion as regulators examine how to stop inappropriate use in infants despite earlier advice. As of this writing, the firm, gazette-backed under-four warning that parents can check on a pack is the one tied to chlorpheniramine maleate and phenylephrine hydrochloride combinations under S.O. 4595(E). Anything broader still has to complete the Drugs Rules amendment path before it becomes mandatory label text.

For school administrators stocking sick-bay shelves, the practical checklist is simple. Read the age warning. Do not treat preschool coughs with leftover adult or toddler syrups. Ask a registered medical practitioner before dosing. And treat the under-four line on these cold FDCs as a hard stop, not a soft suggestion.